Ocrevus 300 mg/10 mL (30 mg/mL) single-dose vial Images
Generic Name: ocrelizumab
This medication has been identified as Ocrevus 300 mg/10 mL (30 mg/mL) single-dose vial. It is supplied by Genentech, Inc.
Ocrevus is used in the treatment of Multiple Sclerosis and belongs to the drug class CD20 monoclonal antibodies. Ocrevus 300 mg/10 mL (30 mg/mL) single-dose vial is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Ocrevus
- Generic Name
- ocrelizumab
- Strength
- 300 mg/10 mL (30 mg/mL) single-dose vial
- Availability
- Prescription only
- Drug Class
- CD20 monoclonal antibodies
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Genentech, Inc.
- National Drug Code (NDC)
- 50242-0150
More about Ocrevus (ocrelizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (161)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: CD20 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
